NCT07109700View on ClinicalTrials.gov

A Study of HDM1005 in Participants With T2DM Not Controlled With Diet/Exercise or Metformin

PHASE2RecruitingINTERVENTIONAL
Enrollment

216

Participants

Timeline

Start Date

April 30, 2025

Primary Completion Date

January 31, 2026

Study Completion Date

February 28, 2026

Conditions
Type 2 Diabetes
Interventions
DRUG

HDM1005 1

administered SC, QW, 20 weeks

DRUG

HDM1005 2

administered SC, QW, 20 weeks

DRUG

HDM1005 3

administered SC, QW, 20 weeks

DRUG

HDM1005 4

administered SC, QW, 20 weeks

DRUG

Placebo

administered SC, QW, 20 weeks

DRUG

Dulaglutide 1.5 MG

administered SC, QW, 20 weeks

Trial Locations (1)

Unknown

RECRUITING

Peking University People's Hospital, Beijing

All Listed Sponsors
lead

Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

INDUSTRY